In this session you'll learn about:
- Principles of a cap table
- Participating and non-participating liquidation preferences
- Dilution through various rounds
- Impact of pre-money valuations on the founders, the various stakeholders, and the company.
Dr. Chris Apfel is an impact investor, board member, and the CEO of SageMedic Corp, (“SAGE”). He is also the Chair of the Life Sciences at the Northern California chapters of the Keiretsu Forum, has led numerous due diligence efforts and has since made over 20+ investments in life science companies including Mission Bio, CorInnova, Pathware, Raydiant Oximetry, etc. Dr. Apfel is also a member, investor, or advisor in other angel groups of funds, such as Kyto Technology and Life Sciences Inc. Before that, he was an Executive Director of Cadence Pharmaceuticals, where his health economic research on a non-reimbursable drug showed a $500 per patient cost savings after which Cadence was acquired for $1.3 billion by Mallinckrodt. Before that he was a practicing clinician at the University of California San Francisco (UCSF) with over 100 peer-reviewed publications, one of which described the Apfel score that became textbook knowledge and changed clinical practice globally. Dr. Apfel received his MD/PhD from the University of Giessen, Germany, and his MBA from Wharton, University of Pennsylvania, PA.
Switch to in-person attendance here: